K A Blum1, S-H Jung2, J L Johnson2, T S Lin3, E D Hsi4, D M Lucas3, J C Byrd3, B D Cheson5, N L Bartlett6. 1. Division of Hematology-Oncology, The Ohio State University Medical Center, Columbus, OH. Electronic address: kristie.blum@osumc.edu. 2. CALGB Statistical Center, Duke University Medical Center, Durham, NC. 3. Division of Hematology-Oncology, The Ohio State University Medical Center, Columbus, OH. 4. Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH. 5. Division of Hematology-Oncology, Georgetown University Hospital, Washington, DC. 6. Division of Hematology-Oncology, Washington University School of Medicine, St Louis, MO, USA.
Abstract
BACKGROUND: Based on in vitro synergistic cytotoxicity when anti-CD30 antibodies are combined with gemcitabine, the Cancer and Leukemia Group B conducted a double-blind, randomized, phase II trial of SGN-30 with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) in patients with relapsed Hodgkin's lymphoma. PATIENTS AND METHODS: In part 1 of the trial, 16 patients received SGN-30 with GVD to assess the safety of the combination. In part 2, patients were randomly allocated to SGN-30 (n = 7) or placebo (n = 7) with GVD to determine overall response rate (ORR). RESULTS:ORR in all 30 patients was 63% (65% with SGN-30 plus GVD, n = 23, and 57% with placebo plus GVD, n = 7). Median event-free survival was 9.0 months, with no difference between the two arms. Grades 3-5 pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closure of the trial. All five patients with pulmonary toxicity had a V/F polymorphism in the FcγRIIIa gene (P = 0.008). CONCLUSIONS: Together with historical data demonstrating a 2% incidence of pulmonary events with GVD, these results indicate that SGN-30 cannot safely be administered concurrently. The risk of pneumonitis with SGN-30 and GVD is greatest in patients with an FcγRIIIa V/F polymorphism.
RCT Entities:
BACKGROUND: Based on in vitro synergistic cytotoxicity when anti-CD30 antibodies are combined with gemcitabine, the Cancer and Leukemia Group B conducted a double-blind, randomized, phase II trial of SGN-30 with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) in patients with relapsed Hodgkin's lymphoma. PATIENTS AND METHODS: In part 1 of the trial, 16 patients received SGN-30 with GVD to assess the safety of the combination. In part 2, patients were randomly allocated to SGN-30 (n = 7) or placebo (n = 7) with GVD to determine overall response rate (ORR). RESULTS: ORR in all 30 patients was 63% (65% with SGN-30 plus GVD, n = 23, and 57% with placebo plus GVD, n = 7). Median event-free survival was 9.0 months, with no difference between the two arms. Grades 3-5 pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closure of the trial. All five patients with pulmonary toxicity had a V/F polymorphism in the FcγRIIIa gene (P = 0.008). CONCLUSIONS: Together with historical data demonstrating a 2% incidence of pulmonary events with GVD, these results indicate that SGN-30 cannot safely be administered concurrently. The risk of pneumonitis with SGN-30 and GVD is greatest in patients with an FcγRIIIa V/F polymorphism.
Authors: C G Cerveny; C-L Law; R S McCormick; J S Lenox; K J Hamblett; L E Westendorf; A K Yamane; J M Petroziello; J A Francisco; A F Wahl Journal: Leukemia Date: 2005-09 Impact factor: 11.528
Authors: A Santoro; H Bredenfeld; L Devizzi; H Tesch; V Bonfante; S Viviani; F Fiedler; H S Parra; C Benoehr; M Pacini; G Bonadonna; V Diehl Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Nancy L Bartlett; Anas Younes; Matthew H Carabasi; Andres Forero; Joseph D Rosenblatt; John P Leonard; Steven H Bernstein; R Gregory Bociek; Jennie M Lorenz; Bruce W Hart; Jeremy Barton Journal: Blood Date: 2007-12-13 Impact factor: 22.113
Authors: Alan F Wahl; Kerry Klussman; Jennifer D Thompson; Judy H Chen; Leigh V Francisco; Grant Risdon; Dana F Chace; Clay B Siegall; Joseph A Francisco Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: R Amakawa; A Hakem; T M Kundig; T Matsuyama; J J Simard; E Timms; A Wakeham; H W Mittruecker; H Griesser; H Takimoto; R Schmits; A Shahinian; P Ohashi; J M Penninger; T W Mak Journal: Cell Date: 1996-02-23 Impact factor: 41.582
Authors: Anita Kumar; Carla Casulo; Joachim Yahalom; Heiko Schöder; Paul M Barr; Philip Caron; April Chiu; Louis S Constine; Pamela Drullinsky; Jonathan W Friedberg; John F Gerecitano; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Alexandra G Jacob; Matthew J Matasar; Gianna N McArthur; Susan J McCall; Alison J Moskowitz; Ariela Noy; Maria L Palomba; Carol S Portlock; David J Straus; Nicholas VanderEls; Stephanie L Verwys; Joanna Yang; Anas Younes; Andrew D Zelenetz; Zhigang Zhang; Craig H Moskowitz Journal: Blood Date: 2016-07-25 Impact factor: 22.113